Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Non-Current Liabilities: 2012-2025

Historic Other Non-Current Liabilities for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $260,000.

  • Enanta Pharmaceuticals' Other Non-Current Liabilities rose 12.55% to $260,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $260,000, marking a year-over-year increase of 12.55%. This contributed to the annual value of $260,000 for FY2025, which is 12.55% up from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Other Non-Current Liabilities stood at $260,000, which was up 3.17% from $252,000 recorded in Q2 2025.
  • Enanta Pharmaceuticals' Other Non-Current Liabilities' 5-year high stood at $994,000 during Q1 2021, with a 5-year trough of $224,000 in Q1 2024.
  • In the last 3 years, Enanta Pharmaceuticals' Other Non-Current Liabilities had a median value of $252,000 in 2025 and averaged $347,091.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first spiked by 56.76% in 2023, then plummeted by 65.16% in 2024.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Other Non-Current Liabilities stood at $856,000 in 2021, then tumbled by 51.64% to $414,000 in 2022, then spiked by 56.76% to $649,000 in 2023, then tumbled by 63.79% to $235,000 in 2024, then rose by 12.55% to $260,000 in 2025.
  • Its Other Non-Current Liabilities was $260,000 in Q3 2025, compared to $252,000 in Q2 2025 and $243,000 in Q1 2025.